4: Polycystic ovary syndrome

Medical Journal of Australia

Volumn 180, Issue 3, 2004, Pages 132-137

  Norman, Robert J ^a,b   Wu, Ruijin ^a   Stankiewicz, Marcin T ^a,b,c  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b Adelaide Hormone and Menopause Ctr   (Australia)

^c Repromed   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; ANTIDIABETIC AGENT; ANTIFUNGAL AGENT; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; CYPROTERONE ACETATE; CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; ESTROGEN; ETHINYLESTRADIOL; FLUTAMIDE; FOLLITROPIN; GESTAGEN; GONADOTROPIN DERIVATIVE; INSULIN SENSITIZING AGENT; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; METFORMIN; NORETHISTERONE; ORAL CONTRACEPTIVE AGENT; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE;

ADOLESCENCE; ADULTHOOD; ANOVULATION; BIOCHEMISTRY; CARDIOVASCULAR DISEASE; CHILDHOOD; CLINICAL FEATURE; DIABETES MELLITUS; DIATHERMY; DIET THERAPY; DOSE RESPONSE; DYSLIPIDEMIA; ECHOGRAPHY; ELECTROLYSIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FERTILIZATION IN VITRO; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GYNECOLOGICAL EXAMINATION; HIRSUTISM; HORMONE DETERMINATION; HUMAN; HYPERANDROGENISM; HYPERLIPIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INFERTILITY; INSULIN RESISTANCE; KINESIOTHERAPY; LIFESTYLE; LIPID ANALYSIS; LONG TERM CARE; MENSTRUATION DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PATHOGENESIS; PATIENT REFERRAL; PELVIS RADIOGRAPHY; PRECOCIOUS PUBERTY; PREGNANCY; PRESCRIPTION; REVIEW; TREATMENT CONTRAINDICATION;

EID: 0842308990     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2004.tb05838.x     Document Type: Review

References (34)

1. Norman RJ. Hyperandrogenaemia and the ovary. Mol Cell Endocrinol 2002; 191: 113-119.
2. Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med 2000; 132: 989-993.
3. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: Towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, editors. Polycystic Ovary Syndrome. Boston: Blackwell, 1992: 377-384.
4. Adams J, Polson DW, Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 1986; 293: 355-359.
5. Farquhar CM, Birdsall M, Manning P, et al. The prevalence of polycystic ovaries on ultrasound scanning in a population of randomly selected women. Aust N Z J Obstet Gynaecol 1994; 34: 67-72.
6. Polson DW, Adams J, Wadsworth J, et al. Polycystic ovaries - A common finding in normal women. Lancet 1988; 1: 870-872.
7. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: A prospective study. J Clin Endocrinol Metab 1998; 83: 3078-3082.
8. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al. A survey of the polycystic ovary syndrome in the Greek island of Lesbos: Hormonal and metabolic profile. J Clin Endocrinol Metab 1999; 84: 4006-4011.
9. Ibanez L, Potau N, Ferrer A, et al. Anovulation in eumenorrheic, nonobese adolescent girls born small for gestational age: Insulin sensitization induces ovulation, increase lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002; 87: 5702-5705.
10. Ibanez L, Potau N, De Zegher F. Ovarian hyporesponsiveness to follicle stimulating hormone in adolescent girls born small for gestational age. J Clin Endocrinol Metab 2000; 85: 2624-2626.
11. Hardiman P, Pillay OS, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003; 361: 1810-1812.
12. Dunaif A, Segal KR, Futterweit W, et al. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989; 38: 1165-1174.
13. Dunaif A. Molecular mechanisms of insulin resistance in the polycystic ovary syndrome. Semin Reprod Endocrinol 1994; 12: 15-20.
14. Pierpoint T, McKeigue PM, Isaacs AJ, et al. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998; 51: 581-586.
15. Norman RJ, Masters L, Milner CR, et al. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001; 16: 1995-1998.
16. Wild S, Pierpoint T, McKeigue P, et al. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: A retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52: 595-600.
17. Talbott EO, Guzick DS, Sutton-Tyrrell K, et al. Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. Arterioscler Thromb Vasc Biol 2000; 20: 2414-2421.
18. Abassi F, Reaver GM. Evaluation of the quantitative insulin sensitivity index as an estimate of insulin sensitivity in humans. Metabolism 2002; 51: 235-237.
19. Legro RS, Finegood D, Dunaif A. A fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694-2698.
20. Ferriman D, Gallwey JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440-1447.
21. Norman RJ, Davies MJ, Lord J, et al. The role of lifestyle modification in polycystic ovary syndrome. Trends Endocrinol Metab 2002; 13: 251-257.
22. Kiddy DS, Hamilton-Fairley D, Seppala M, et al. Diet-induced changes in sex hormone binding globulin and free testosterone in women with normal or polycystic ovaries: Correlation with serum insulin and insulin-like growth factor-I. Clin Endocrinol (Oxf) 1989; 31: 757-763.
23. Pasquali R, Antenucci D, Casimirri F, et al. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989; 68: 173-179.
24. Clark AM, Ledger W, Galletly C, et al. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705-2712.
25. Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13: 1502-1505.
26. Moran LJ, Noakes M, Clifton PM, et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003; 88: 812-819.
27. Huber-Buchholz MM, Carey DG, Norman RJ. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: Role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470-1474.
28. Norman RJ, Kidson WJ, Cuneo RC, et al. Metformin and intervention in polycystic ovary syndrome: Endocrine Society of Australia, the Australian Diabetes Society and the Australian Paediatric Endocrine Group. Med J Aust 2001; 174: 580-583.
29. Lord JM, Flight IH, Norman RJ: Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev 2003; (3): CD003053.
30. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ 2003; 327: 951.
31. Kidson W. Polycystic ovary syndrome: A new direction in treatment. Med J Aust 1998; 169: 537-540.
32. Azziz R, Ehrmann D, Legro RS, et al. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86: 1626-1632.
33. Tarrade A, Schoonjans K, Pavan L, et al. PPARgamma/RXRalpha heterodimers control human trophoblast invasion. J Clin Endocrinol Metab 2001; 86: 5017-5024.
34. Farquhar C, Vandekerchkove P, Lilford R. Laparoscopic "drilling" by diathermy or laser for ovulation induction in anovulatory polycystic ovary syndrome (Cochrane Review). The Cochrane Library, Issue 2, 2003. Oxford: Update Software.